News | 12 May 2023
Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The Awards recognizes standout digital health & medical technology products and companies
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Tatva Chintan Pharma Chem has reported total income of Rs. 125.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
